Skip to content

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women in the Kingdom of Bahrain

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01205412
Enrollment
552
Registered
2010-09-20
Start date
2010-10-31
Completion date
2011-11-30
Last updated
2012-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Papillomavirus Infection

Brief summary

The purpose of this study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for post-natal check up in the Kingdom of Bahrain.

Interventions

Endocervical samples collection during routine gynaecological examinations

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women ≥ 20 years of age attending a clinic for routine cervical screening OR * Women ≥ 16 years of age presenting for post-natal check-ups * Women providing a cervical sample * Written informed consent or oral-witnessed thumb printed informed consent obtained from the subject

Exclusion criteria

* Referral for abnormal cervical sample at the current visit * Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed (Note: Enrolment can be delayed until this condition is resolved) * Pregnant women * History of hysterectomy * Known diagnosis of immunosuppression, or patient on immunosuppressives * Having received one or more doses of human papillomavirus vaccine prior to participating in the study

Design outcomes

Primary

MeasureTime frame
Prevalence of any Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) and HPV type distribution among women undergoing cervical sample testing and post-natal check up.Average time frame: 12 months

Secondary

MeasureTime frame
Prevalence of any HPV DNA and HPV type distribution among women of different age strata undergoing cervical sample testing and post-natal check up.Average time frame: 12 months
Behavioural risk factorsDuring visit 1 (day 0)
Awareness of HPV in relation to transmission and cause of cervical cancerAverage time frame: 12 months

Countries

Bahrain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026